478 related articles for article (PubMed ID: 25307749)
1. Prognostic impact of neoadjuvant chemoradiation in cT3 oesophageal cancer - A propensity score matched analysis.
Hölscher AH; Bollschweiler E; Bogoevski D; Schmidt H; Semrau R; Izbicki JR
Eur J Cancer; 2014 Nov; 50(17):2950-7. PubMed ID: 25307749
[TBL] [Abstract][Full Text] [Related]
2. Molecular Markers for the Prediction of Minor Response to Neoadjuvant Chemoradiation in Esophageal Cancer: Results of the Prospective Cologne Esophageal Response Prediction (CERP) Study.
Bollschweiler E; Hölscher AH; Herbold T; Metzger R; Alakus H; Schmidt H; Drebber U; Warnecke-Eberz U
Ann Surg; 2016 Nov; 264(5):839-846. PubMed ID: 27741011
[TBL] [Abstract][Full Text] [Related]
3. Prognostic classification of histopathologic response to neoadjuvant therapy in esophageal adenocarcinoma.
Hölscher AH; Drebber U; Schmidt H; Bollschweiler E
Ann Surg; 2014 Nov; 260(5):779-84; discussion 784-5. PubMed ID: 25379849
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemotherapy or chemoradiation for patients with advanced adenocarcinoma of the oesophagus? A propensity score-matched study.
Favi F; Bollschweiler E; Berlth F; Plum P; Hescheler DA; Alakus H; Semrau R; Celik E; Mönig SP; Drebber U; Hölscher AH
Eur J Surg Oncol; 2017 Aug; 43(8):1572-1580. PubMed ID: 28666624
[TBL] [Abstract][Full Text] [Related]
5. Early surgery for failure after chemoradiation in operable thoracic oesophageal cancer. Analysis of the non-randomised patients in FFCD 9102 phase III trial: Chemoradiation followed by surgery versus chemoradiation alone.
Vincent J; Mariette C; Pezet D; Huet E; Bonnetain F; Bouché O; Conroy T; Roullet B; Seitz JF; Herr JP; Di Fiore F; Jouve JL; Bedenne L;
Eur J Cancer; 2015 Sep; 51(13):1683-93. PubMed ID: 26163097
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemoradiation for patients with advanced oesophageal cancer - which response grading system best impacts prognostic discrimination?
Puetz K; Bollschweiler E; Semrau R; Mönig SP; Hölscher AH; Drebber U
Histopathology; 2019 Apr; 74(5):731-743. PubMed ID: 30636069
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of extracapsular lymph node involvement after neoadjuvant therapy and oesophagectomy.
Lagarde SM; Navidi M; Gisbertz SS; van Laarhoven HW; Sumpter K; Meijer SL; Disep B; Immanuel A; Griffin SM; van Berge Henegouwen MI
Br J Surg; 2016 Nov; 103(12):1658-1664. PubMed ID: 27696382
[TBL] [Abstract][Full Text] [Related]
8. Comparison of survival among neoadjuvant chemoradiation responders, non-responders and patients receiving primary resection for locally advanced oesophageal squamous cell carcinoma: does neoadjuvant chemoradiation benefit all?
Hsu PK; Chien LI; Huang CS; Hsieh CC; Wu YC; Hsu WH; Chou TY
Interact Cardiovasc Thorac Surg; 2013 Sep; 17(3):460-6. PubMed ID: 23728085
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Relevance of Lymph Node Regression After Neoadjuvant Chemoradiation for Esophageal Cancer.
Philippron A; Bollschweiler E; Kunikata A; Plum P; Schmidt C; Favi F; Drebber U; Hölscher AH
Semin Thorac Cardiovasc Surg; 2016 Summer; 28(2):549-558. PubMed ID: 28043475
[TBL] [Abstract][Full Text] [Related]
10. Radiation dose and pathological response in oesophageal cancer patients treated with neoadjuvant chemoradiotherapy followed by surgery: a multi-institutional analysis.
Thomas M; Borggreve AS; van Rossum PSN; Perneel C; Moons J; Van Daele E; van Hillegersberg R; Deng W; Pattyn P; Mook S; Boterberg T; Ruurda JP; Nafteux P; Lin SH; Haustermans K
Acta Oncol; 2019 Oct; 58(10):1358-1365. PubMed ID: 31432736
[No Abstract] [Full Text] [Related]
11. [Therapeutic decisions in patients with operable, non-metastatic oesophageal cancer].
Fuchs HF; Hölscher AH
Zentralbl Chir; 2014 Feb; 139(1):32-6. PubMed ID: 24585195
[TBL] [Abstract][Full Text] [Related]
12. Outcome of neoadjuvant therapies for cancer of the oesophagus or gastro-oesophageal junction based on a national data registry.
Klevebro F; Lindblad M; Johansson J; Lundell L; Nilsson M
Br J Surg; 2016 Dec; 103(13):1864-1873. PubMed ID: 27689845
[TBL] [Abstract][Full Text] [Related]
13. Role of neoadjuvant treatment in clinical T2N0M0 oesophageal cancer: results from a retrospective multi-center European study.
Markar SR; Gronnier C; Pasquer A; Duhamel A; Beal H; Théreaux J; Gagnière J; Lebreton G; Brigand C; Meunier B; Collet D; Mariette C;
Eur J Cancer; 2016 Mar; 56():59-68. PubMed ID: 26808298
[TBL] [Abstract][Full Text] [Related]
14. Impact of postoperative TNM stages after neoadjuvant therapy on prognosis of adenocarcinoma of the gastro-oesophageal junction tumours.
Thomaschewski M; Hummel R; Petrova E; Knief J; Wellner UF; Keck T; Bausch D
World J Gastroenterol; 2018 Apr; 24(13):1429-1439. PubMed ID: 29632424
[TBL] [Abstract][Full Text] [Related]
15. CMISG1701: a multicenter prospective randomized phase III clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma (cT
Tang H; Tan L; Shen Y; Wang H; Lin M; Feng M; Xu S; Guo W; Qian C; Liu T; Zeng Z; Hou Y; Yu Z; Jiang H; Li Z; Chen C; Lian C; Du M; Li H; Xie D; Yin J; Zhao N; Wang Q
BMC Cancer; 2017 Jun; 17(1):450. PubMed ID: 28659128
[TBL] [Abstract][Full Text] [Related]
16. The presence of lymphovascular and perineural infiltration after neoadjuvant therapy and oesophagectomy identifies patients at high risk for recurrence.
Lagarde SM; Phillips AW; Navidi M; Disep B; Immanuel A; Griffin SM
Br J Cancer; 2015 Nov; 113(10):1427-33. PubMed ID: 26554656
[TBL] [Abstract][Full Text] [Related]
17. Association Between Clinically Staged Node-Negative Esophageal Adenocarcinoma and Overall Survival Benefit From Neoadjuvant Chemoradiation.
Gabriel E; Attwood K; Du W; Tuttle R; Alnaji RM; Nurkin S; Malhotra U; Hochwald SN; Kukar M
JAMA Surg; 2016 Mar; 151(3):234-45. PubMed ID: 26559488
[TBL] [Abstract][Full Text] [Related]
18. Morbidity and mortality after surgery for cancer of the oesophagus and gastro-oesophageal junction: A randomized clinical trial of neoadjuvant chemotherapy vs. neoadjuvant chemoradiation.
Klevebro F; Johnsen G; Johnson E; Viste A; Myrnäs T; Szabo E; Jacobsen AB; Friesland S; Tsai JA; Persson S; Lindblad M; Lundell L; Nilsson M
Eur J Surg Oncol; 2015 Jul; 41(7):920-6. PubMed ID: 25908010
[TBL] [Abstract][Full Text] [Related]
19. Different recurrence pattern after neoadjuvant chemoradiotherapy compared to surgery alone in esophageal cancer patients.
Smit JK; Güler S; Beukema JC; Mul VE; Burgerhof JG; Hospers GA; Plukker JT
Ann Surg Oncol; 2013 Nov; 20(12):4008-15. PubMed ID: 23838922
[TBL] [Abstract][Full Text] [Related]
20. Worldwide Oesophageal Cancer Collaboration guidelines for lymphadenectomy predict survival following neoadjuvant therapy.
Stiles BM; Nasar A; Mirza FA; Lee PC; Paul S; Port JL; Altorki NK
Eur J Cardiothorac Surg; 2012 Oct; 42(4):659-64. PubMed ID: 22491667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
